REGN Regeneron Pharmaceuticals, Inc. — dividend yield, history & ex-dividend dates
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Dividend Snapshot
Key Metrics
Current Yield
0.48%
At the Sep 14, 2026 price
The annual dividend as a percentage of the share price. A 3% yield is about $3 of dividends a year for every $100 invested at today's price.Annualized Dividend
$3.7600
The most recent payment scaled to a full year by how often it's paid. A $0.25 quarterly dividend annualizes to $1.00.Frequency
Q Quarterly
How often the dividend is paid: Q = quarterly (4x a year), M = monthly, S = semi-annual, A = annual.Rank Score
44.6
As of Sep 14, 2026
Our 0-100 house score blending yield quality, payout sustainability (the trailing-twelve-month payout ratio), profitability (TTM return on equity), valuation (TTM price-to-book) and payment reliability, recomputed daily. Higher means a stronger profile on those factors in our model — a research score, not advice or a recommendation to buy.RSI (14)
46
As of Sep 14, 2026
Relative Strength Index (0-100), a price-momentum gauge. Above 70 is often called 'overbought', below 30 'oversold'. A technical signal, not a dividend metric.52-Week Range
$555.51 – $852.03
Closes through Sep 11, 2026
The lowest and highest price over the past year — shows where today's price sits in its recent range.Payout Ratio (TTM)
8.74%
12 months to Jun 30, 2026 (Q2 FY2026)
The share of earnings paid out as dividends over the trailing twelve months (TTM): dividends paid divided by net income across the company's four most recent reported quarters, dated by the latest quarter end. A fiscal-year tag such as FY2025 means only annual figures were available. Lower leaves more cushion; above 100% means paying out more than the company earned. It shows n/a for funds and when net income over the period was negative; for REITs and BDCs it is marked EPS-based, since they are judged on FFO/AFFO or net investment income instead.Years Paying
1
How many years of payments we have on record. This can understate very long histories where our data doesn't reach far enough back.Price / Book (TTM)
2.55
Price as of Sep 14, 2026; latest reported book value
Price-to-book ratio: the share price on the date shown divided by the latest reported book value per share. A rough valuation gauge, most useful for asset-heavy sectors like REITs, banks and insurers.S.A.F.E. Dividend Read
Quote & Key Data
Dividend Growth
Why the Yield Moved (90 Days)
REGN's dividend yield fell from 0.61% to 0.48% over the past ~90 days (-0.13 pp). Of that move, +0.00 pp came from changes in the dividend rate and -0.13 pp from the share price ($614.73 on Jun 16, 2026 → $781.49 on Sep 14, 2026). A yield that rises because the price fell is not an improvement in the payout itself.
Yield vs Its Own History
Across 333 daily observations over the past 16 months (through Sep 11, 2026), REGN's current yield is higher than approximately 26% of them. Our stored price history for REGN covers the past 16 months; 3- and 5-year averages are not yet computable from it and are deliberately not shown.
Adjusted Price History
Dividend History
Dividend Payment History
Ex-dividend calendar →| Amount | Type | Declared | Ex-Date | Record | Pay |
|---|---|---|---|---|---|
| $0.9400 Q | Regular | Jul 30, 2026 | Aug 18, 2026 | Aug 18, 2026 | Aug 31, 2026 |
| $0.9400 Q | Regular | Apr 29, 2026 | May 20, 2026 | May 20, 2026 | Jun 04, 2026 |
| $0.9400 Q | Regular | Jan 30, 2026 | Feb 20, 2026 | Feb 20, 2026 | Mar 05, 2026 |
| $0.8800 Q | Regular | Oct 28, 2025 | Nov 20, 2025 | Nov 20, 2025 | Dec 05, 2025 |
| $0.8800 Q | Regular | Aug 01, 2025 | Aug 18, 2025 | Aug 18, 2025 | Sep 03, 2025 |
| $0.8800 Q | Regular | Apr 29, 2025 | May 20, 2025 | May 20, 2025 | Jun 06, 2025 |
| $0.8800 Q | Regular | Feb 04, 2025 | Feb 20, 2025 | Feb 20, 2025 | Mar 20, 2025 |
Peer Comparison
Selected Biotechnology dividend payers we cover, strongest DividendRank first — for context, not a recommendation.
| Ticker | Name | Yield | 5-Yr Growth | Streak | Rank |
|---|---|---|---|---|---|
| TRSBF | 3SBio Inc. | 1.48% | - | 0 yrs | 62 |
| XOMAP | XOMA Corporation | 8.63% | - | 0 yrs | 54 |
| XOMAO | XOMA Corporation | 8.38% | - | 0 yrs | 52 |
| TECH | Bio-Techne Corporation | 0.44% | 0.0% | 0 yrs | 39 |
Related Guides & Lists
REGN dividend — frequently asked questions
Does Regeneron Pharmaceuticals, Inc. pay a dividend?
Yes. Regeneron Pharmaceuticals, Inc. (REGN) currently pays a dividend. The annualized dividend is about $3.76 per share, a yield of approximately 0.48%.
What is Regeneron Pharmaceuticals, Inc.'s dividend yield?
Regeneron Pharmaceuticals, Inc.'s dividend yield is approximately 0.48%, based on the most recent regular payment annualized against the current share price. Yields move as the share price changes.
How often does Regeneron Pharmaceuticals, Inc. pay dividends?
Regeneron Pharmaceuticals, Inc. pays dividends quarterly — 4 times per year.
How long has Regeneron Pharmaceuticals, Inc. paid dividends?
Regeneron Pharmaceuticals, Inc. has 1 years of dividend payments on record.
Data updated Sep 14, 2026. This research page is generated from Dividendly's structured market and dividend dataset using the approach described on our methodology and data sources pages. Data is automatically validated using defined rules and may also be periodically reviewed. Research only, not investment advice. Spotted a data error? Report it.